Oseltamivir azido derivative as well as preparation method and application thereof

By discovering and preparing oseltamivir azide impurities 338 and 340 and using them as reference materials for quality control, the problem of difficult control of impurities in oseltamivir phosphate is solved, and safety risks and guarantees are achieved Drug quality goals.

CN119019280AActive Publication Date: 2024-11-26ZHONGSHAN WANHAN PHARM CO LTD +1
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202411140392.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-26
Estimated Expiration
2044-08-20

AI Technical Summary

Technical Problem

During the preparation of oseltamivir phosphate, oseltamivir azide-based impurities exist, which affects the quality and safety of the drug. It is difficult for the prior art to effectively detect and control its content.

Method used

Impurities 338 and 340 were discovered and identified, and their preparation method was prepared, and their content in oseltamivir phosphate was reduced through specific reaction conditions and purification processes, and used as a reference for quality control to ensure that The content is not higher than 30ppm.

Benefits of technology

It effectively reduces the content of impurities in oseltamivir phosphate, reduces the safety risks during drug use, and ensures that the quality of the drug meets the standards.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019280A_ABST
    Figure CN119019280A_ABST
Patent Text Reader

Abstract

The invention discloses an oseltamivir azido derivative. The structure of the oseltamivir azido derivative is shown as an impurity 338 or an impurity 340. The two impurities are found for the first time in the oseltamivir phosphate preparation process and have obvious toxicity, so that it is necessary to control the content of the two impurities in the oseltamivir phosphate to be not higher than 30 ppm so as to reduce the safety risk existing in the oseltamivir phosphate use process. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drug synthesis and analysis, and to impurities in the production process of raw materials, preparation and analysis and detection thereof; more specifically, to an oseltamivir azido derivative, a preparation method and use of the derivative as a reference substance in quality control. Background Art

[0002] Oseltamivir phosphate (OST) is a potent antiviral drug used to treat influenza A and B that inhibits the viral enzyme neuraminidase, preventing viral budding from host cells, infectivity, and replication. Oseltamivir phosphate is an ester prodrug that is metabolized to oseltamivir carboxylate in the liver by liver esterases; its half-life is 1.8 hours, and after oral administration, 80% of the metabolites show therapeutic effects for about 30 minutes, and 20% of the drug will be present in plasma for 3-4 hours.

[0003] Oseltamivir phosphate was first approved by the FDA in October 1999. Its dosage for the treatment of influenza in adults is 75 mg twice a day for five consecutive days, while its dosage for the prevention of influenza in adults is 75 mg once a day for 10 consecutive days. The structure of oseltamivir phosphate is as follows:

[0004]

[0005] The Oseltamivir Phosphate monograph of USP2021 discloses an oseltamivir azido-related substance with a structure as shown in Formula I, which may be introduced by the use of sodium azide in the synthesis and preparation process of the raw material. PikkiliViswanath et al. defined the compound shown in Formula I as a genotoxic impurity in the article Method Development and Validation for the Trace Level Quantification of Genotoxic Impurity Oseltamivir Phosphate Related Compound-A in Oseltamivir Phosphate using LC-MS, and proposed an effective control method.

[0006]

[0007] John C. Rohloff et al. disclosed in the article "Practical Total Synthesis of the Anti-Influenza Drug GS-4104" (Source: J. Org. Chem. 1998, 63, 13, 4545-4550, hereinafter referred to as "Document 1") the route and method for preparing oseltamivir phosphate from AS7 as shown below.

[0008]

[0009] AS9 is one of the commonly used intermediates in the synthesis of oseltamivir phosphate API. It is prepared from AS7 by sequentially undergoing azidation ring-opening and acetylation reactions. There are multiple sites on the cyclohexene ring in the AS7 structure where nucleophilic addition reactions of the azide group can occur, which may generate impurities of AS9 analogs and remain in the oseltamivir phosphate API, thereby having unpredictable effects on the quality of the oseltamivir phosphate API and its preparations. Summary of the invention

[0010] The object of the present invention is to provide an oseltamivir azido derivative, which is first discovered in the preparation process of oseltamivir phosphate and obtained after identification, and is an impurity of oseltamivir phosphate.

[0011] Another object of the present invention is to provide a method for preparing the oseltamivir azido derivative.

[0012] Another object of the present invention is to provide the use of oseltamivir azido derivatives as reference substances in the quality control of oseltamivir phosphate.

[0013] Another object of the present invention is to provide a method for quality control of oseltamivir phosphate.

[0014] The above-mentioned purpose of the present invention is achieved through the following scheme:

[0015] An oseltamivir azido derivative, whose structure is one of impurity 338 or impurity 340:

[0016]

[0017] In the preparation process of oseltamivir phosphate, the present invention first discovered two compounds, impurity 338 and impurity 340; even if oseltamivir is made into oseltamivir phosphate after recrystallization, the content of these two impurities is significantly reduced, but they may still exist in oseltamivir phosphate; in view of the relatively obvious toxicity of these two impurities, it is necessary to detect the content of these two impurities in oseltamivir phosphate to control the content not exceeding the prescribed limit. According to the TTC method calculation of ICH M7, the content of these two impurities in oseltamivir phosphate needs to be controlled to be no more than 30ppm to meet the standard.

[0018] The present invention also protects the preparation method of impurity 338 and impurity 340. The preparation process of impurity 338 and impurity 340 is as follows: AS7, ammonium chloride and sodium azide are mixed and dissolved in N,N-dimethylformamide, and heated to react under an inert gas atmosphere; after the reaction is completed, the solvent is removed, the obtained mixture is dissolved in dichloromethane, and triethylamine and acetic anhydride are added, and the reaction is carried out under low temperature conditions; after the reaction is completed, the solvent is removed, and the target compound is obtained after purification.

[0019] Preferably, in the preparation process of impurities 33 and 340, the molar ratio of AS7 to ammonium chloride and sodium azide is 1:1.7-2.2:2.0-3.0. More preferably, in the preparation process of impurities 33 and 340, the molar ratio of AS7 to ammonium chloride and sodium azide is 1:1.9-2.1:2.2-2.7.

[0020] More preferably, during the preparation of impurity 33 and impurity 340, the molar ratio of AS7 to ammonium chloride and sodium azide is 1:2:2.5.

[0021] Preferably, in the preparation process of impurity 33 and impurity 340, the molar ratio of AS7 to triethylamine and acetic anhydride is 1:1.0-1.5:0.7-1.2.

[0022] More preferably, in the preparation process of impurity 33 and impurity 340, the molar ratio of AS7 to triethylamine and acetic anhydride is 1:1.0-1.3:0.9-1.0.

[0023] More preferably, in the preparation process of impurity 33 and impurity 340, the molar ratio of AS7 to triethylamine and acetic anhydride is 1:1.2:0.98.

[0024] Preferably, during the preparation of impurities 33 and 340, the temperature of the heating reaction under an inert gas atmosphere is 50-70°C; more preferably, the temperature is 60°C.

[0025] Preferably, the inert gas is nitrogen.

[0026] Preferably, the reaction temperature under low temperature conditions is 0-5°C.

[0027] The present invention also protects the use of oseltamivir azido derivatives as reference substances in the quality control of oseltamivir phosphate.

[0028] Preferably, the masses of impurities 338 and 340 in oseltamivir phosphate are controlled to be no higher than 30 ppm.

[0029] The present invention also protects a method for quality control of oseltamivir phosphate, that is, using impurity 338 and / or impurity 340 as reference substances for detection and analysis, and controlling the content of impurity 338 and impurity 340 in oseltamivir phosphate.

[0030] Preferably, the masses of impurities 338 and 340 in oseltamivir phosphate are controlled to be no higher than 30 ppm.

[0031] Compared with the prior art, the present invention has the following beneficial effects:

[0032] In the preparation process of oseltamivir phosphate, the present invention first discovered two impurities, impurity 338 and impurity 340, and these two impurities have obvious toxicity. Therefore, it is necessary to control the content of these two impurities in oseltamivir phosphate to be no more than 30 ppm, so as to reduce the safety risks in the use of oseltamivir phosphate. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 The HPLC detection and analysis results of the AS9 sample in Example 1 are shown.

[0034] Figure 2 The HPLC detection and analysis results of the crude oseltamivir phosphate in Example 1 are shown.

[0035] Figure 3 This is the mass spectrum of impurity 338.

[0036] Figure 4 This is the mass spectrum of impurity 340.

[0037] Figure 5 For impurity 338 1 H-NMR spectrum.

[0038] Figure 6 For impurity 338 13 C-NMR spectrum.

[0039] Figure 7 For impurity 340 1 H-NMR spectrum.

[0040] Figure 8 For impurity 340 13 C-NMR spectrum. DETAILED DESCRIPTION

[0041] The present invention is further described in detail below in conjunction with specific examples, which are only used to explain the present invention and are not used to limit the scope of the present invention. The test methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.

[0042] Example 1 Discovery of Impurities 338 and 340

[0043] Oseltamivir phosphate is prepared by reaction using AS7 as a raw material (AS7 is a commercial product). The specific reaction process is carried out according to the steps described in document 1: John C. Rohloff, Kenneth M. Kent, Michael J. Postich, et al. Practical Total Synthesis of the Anti-Influenza Drug GS-4104. J. Org. Chem. 1998, 63, 4545-4550. The reaction route is as follows:

[0044]

[0045]

[0046] AS7, AS8 and AS9 in the above route correspond to compound 19, compound 6 and compound 20 in document 1, respectively; that is, the preparation of AS8 is to use AS7 as a reaction material and to react with reference to the preparation process of compound 6 in document 1 to obtain AS8; then, using AS8 as a reaction material and to react with reference to the preparation process of compound 20 in document 1 to obtain AS9. Finally, AS9 is subjected to an Aza-Wittig reaction to obtain a free base AS10, which is then salted to obtain oseltamivir phosphate.

[0047] AS9 Analysis Methods

[0048] Take the AS9 sample prepared by the above method, add 50% acetonitrile solution to dissolve and dilute to make a solution containing about 1 mg per 1 mL, as the test solution; take an appropriate amount of oseltamivir intermediate AS9 phosphate reference substance (purchased from outside), add 50% acetonitrile solution to dissolve and dilute to make a solution containing about 1 mg of oseltamivir intermediate AS9 phosphate per 1 mL, as the reference substance solution. According to the high performance liquid chromatography method (Chinese Pharmacopoeia 2015 Edition Four General Rules 0512), octadecylsilane bonded silica gel is used as a filler (Kromasil C184.6mm×250mm, 5μm or a chromatographic column with equivalent performance); 0.01mol / L potassium dihydrogen phosphate solution (adjusted to pH 6.0 with 1mol / L potassium hydroxide solution)-acetonitrile (45:55) is used as the mobile phase; the detection wavelength is 207nm. Accurately measure 20 μL of the reference solution and the test solution, respectively, and inject them into the liquid chromatograph, and record the chromatogram to 4 times the retention time of the main peak.

[0049] AS9 sample testing and analysis results

[0050] The HPLC test results of AS9 samples are shown in Figure 1 The retention times are 3.974min and 9.002min for impurity 340 and impurity 338 respectively.

[0051] Acquisition and structural confirmation of target impurities: About 2 g of AS9 sample was taken and separated and purified by semi-preparative liquid chromatography (chromatographic column: HPLCONE-5C18C (30 mm ID×250 mm), detection wavelength: 207 nm, flow rate: 20 mL / min, column temperature: 25°C, mobile phase: acetonitrile-water (45:55)), and the impurities were collected and purified. Figure 1 The elution components corresponding to the retention times are 3.974min and 9.002min.

[0052] The mass spectrum of the component corresponding to RT 9.002min is shown in Figure 3 .

[0053] The mass spectrum of the component corresponding to RT 3.974min is shown in Figure 4 .

[0054] RT 9.002min corresponding to the component 1 H-NMR and 13 C-NMR diagrams are shown in Figure 5 and Figure 6 .

[0055] RT 3.974min corresponding to the component 1 H-NMR and 13 C-NMR diagrams are shown in Figure 7 and Figure 8 .

[0056] After identification, Figure 1 The structures of the components corresponding to RT 9.002min and RT 3.974min are shown in impurity 338 and impurity 340 respectively:

[0057]

[0058] Analysis of Crude Oseltamivir Phosphate

[0059] Test solution: Take about 30 mg of sample, weigh accurately, place in a 10 mL volumetric flask, add mobile phase to dilute to the scale, shake well, and obtain.

[0060] Analytical methods

[0061] Determined by high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition) and tandem mass spectrometry (General Rules 0431 of Part IV of the Chinese Pharmacopoeia 2020 Edition).

[0062] Chromatographic conditions:

[0063] Chromatographic column: Octadecylsilane bonded silica gel as filler (Kromasi1 C18 4.6mm×250mm, 5μm or chromatographic column with equivalent performance);

[0064] Mobile phase: 0.01 mol / L potassium dihydrogen phosphate solution (adjust pH to 6.0 with 1 mol / L potassium hydroxide solution)-acetonitrile (45:55);

[0065] Detection wavelength: 207nm;

[0066] Flow rate: 1.0ml / min;

[0067] Column temperature: 35 °C;

[0068] The injection volume was 20 μL.

[0069] Oseltamivir phosphate sample testing and analysis results

[0070] Figure 2 In the experiment, the peak retention time of impurity 338 was RT19.135min, and the peak retention time of impurity 340 was RT12.483min.

[0071] Example 2 Preparation of Impurity 338 and Impurity 340

[0072] Take a certain amount of AS7, dissolve it in N,N-dimethylformamide (2g / mL relative to AS7) at 20℃, then add ammonium chloride (2 times the molar mass of AS7) and sodium azide (2.5 times the molar mass of AS7), replace nitrogen and stir at 60℃ for 42h. After the reaction, remove the solvent by vacuum distillation, dissolve the solid mixture in dichloromethane (3.2 times v / w relative to the solid mixture), add triethylamine (1.2 times the molar mass of AS7), cool to 0-5℃, add acetic anhydride (0.98 times the molar mass of AS7) dropwise, add dropwise for about 1h, and the reaction is complete in 2-3h. The solvent was removed by distillation under reduced pressure, and the product was separated and purified by semi-preparative liquid chromatography (chromatographic column: HPLCONE-5C18C (30 mm ID×250 mm), detection wavelength: 207 nm, flow rate: 20 mL / min, column temperature: 25°C, mobile phase: acetonitrile-water (45:55)) to obtain impurity 338 and impurity 340 with yields (relative to AS7) of 30.2% and 28.7%, respectively.

[0073] Example 3 In vitro cytotoxicity test of impurities 338 and 340

[0074] The cytotoxicity of impurities 338 and 340 was tested using the method disclosed in the prior art. The results are shown in Table 1.

[0075] Table 1 Cytotoxicity results of impurities 338 and 340

[0076]

[0077] It can be seen from the above table that impurities 338 and impurity 340 are significantly toxic to at least one of the liver L02 cells, myocardial H9c2 cells, embryonic kidney HEK-293 cells and neural SH-SY5Y cells. If their concentrations in the drug are not controlled, they are very likely to produce certain toxic side effects.

[0078] It is also worth pointing out that although Figure 1 The contents of various impurities in oseltamivir phosphate are all lower than 0.1%. However, in the actual process, many factors will cause fluctuations in the impurity content, including but not limited to: ① Equipment modification or upgrading; ② The proficiency of process personnel; ③ Changes in batches, etc. And in view of the obvious toxicity of impurities 338 and 340, according to the TTC method of ICH M7, the contents of these two impurities in oseltamivir phosphate need to be controlled to be no higher than 30ppm to meet the standards. Therefore, for safety reasons, it is necessary to test the contents of these two impurities in oseltamivir phosphate to control their contents to meet the standards. This requires the use of impurities 338 and 340 as impurity reference substances for detection and analysis.

[0079] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit the protection scope of the present invention. For ordinary technicians in this field, other different forms of changes or modifications can be made based on the above descriptions and ideas. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. An oseltamivir azido derivative, characterized in that: Its structure is one of impurity 338 or impurity 340:

2. The method for preparing the oseltamivir azido derivative according to claim 1, characterized in that: The preparation process of impurity 338 and impurity 340 is as follows: AS7 is mixed with ammonium chloride and sodium azide in N,N-dimethylformamide and heated to react under an inert gas atmosphere; after the reaction is completed, the solvent is removed, the resulting mixture is dissolved in dichloromethane, and triethylamine and acetic anhydride are added to react under low temperature conditions; after the reaction is completed, the solvent is removed and the target compound is obtained after purification.

3. The method for preparing the oseltamivir azido derivative according to claim 2, characterized in that: During the preparation of impurities 338 and 340, the molar ratio of AS7 to ammonium chloride and sodium azide is 1:1.7-2.2:2.0-3.

0.

4. The method for preparing the oseltamivir azido derivative according to claim 2, characterized in that: During the preparation of impurity 338 and impurity 340, the molar ratio of AS7 to triethylamine and acetic anhydride is 1:1.0-1.5:0.7-1.

2.

5. The method for preparing the oseltamivir azido derivative according to claim 2, characterized in that: During the preparation of impurities 338 and 340, the heating reaction temperature is 50-70° C. under an inert gas atmosphere.

6. Use of the oseltamivir azido derivative according to claim 1 as a reference substance in the quality control of oseltamivir phosphate.

7. The use according to claim 6, characterized in that: The masses of impurity 338 and impurity 340 in oseltamivir phosphate are controlled to be no higher than 30 ppm.

8. A method for quality control of oseltamivir phosphate, characterized in that: Impurity 338 and / or impurity 340 are used as reference substances for detection and analysis to control the content of impurity 338 and impurity 340 in oseltamivir phosphate.

9. The method for quality control of oseltamivir phosphate according to claim 8, characterized in that: The masses of impurity 338 and impurity 340 in oseltamivir phosphate are controlled to be no higher than 30 ppm.

Citation Information

Patent Citations

  • Application of FSO2N3 in preparation of azide

    CN110590485A

  • Composition containing para-aminobenzoic acid derivatives and fatty hexatomic-ring carboxylic acid derivatives, and application thereof

    CN110840871A

  • Composition containing fatty hexatomic-ring carboxylic acid derivative and use of composition

    CN111329868A

  • Anti-influenza virus composition containing polyol and aliphatic hexacyclic-ring carboxylic acid derivative and application of anti-influenza virus composition

    CN111388486A

  • Method for preparing oseltamivir phosphate by azide process

    CN111747861A